The smallest drug-eluting stent (DES) available in the United States has received FDA approval. At 2.0 mm, the new stent is intended to help interventional cardiologists treat patients with coronary artery disease whose small vessels often can’t be treated with larger stents during percutaneous coronary intervention.
Approval of the Resolute Onyx 2.0 mm DES was supported by data presented at the 2017 EuroPCR annual meeting for interventional cardiologists. The clinical study involved 101 patients with coronary lesions between 2.0 and 2.25 mm in diameter. Patients were enrolled at 20 sites in the United States and Japan.
Voelker R. New Stent for Small Vessels. JAMA. 2018;319(13):1314. doi:10.1001/jama.2018.2942
Customize your JAMA Network experience by selecting one or more topics from the list below.